Moloney Securities Asset Management LLC lessened its stake in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 52.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,854 shares of the company’s stock after selling 5,406 shares during the quarter. Moloney Securities Asset Management LLC’s holdings in Moderna were worth $202,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of MRNA. Wilmington Savings Fund Society FSB grew its holdings in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its position in Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after buying an additional 389 shares during the last quarter. Blue Trust Inc. grew its stake in shares of Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock valued at $47,000 after acquiring an additional 388 shares in the last quarter. EMC Capital Management grew its stake in shares of Moderna by 311.2% during the fourth quarter. EMC Capital Management now owns 1,250 shares of the company’s stock valued at $52,000 after acquiring an additional 946 shares in the last quarter. Finally, Larson Financial Group LLC increased its position in shares of Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after acquiring an additional 317 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.
Insiders Place Their Bets
In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders sold 2,664 shares of company stock worth $115,210. Insiders own 15.20% of the company’s stock.
Analyst Ratings Changes
Read Our Latest Analysis on MRNA
Moderna Stock Down 2.9 %
MRNA stock opened at $30.93 on Wednesday. The stock has a market cap of $11.90 billion, a PE ratio of -5.31 and a beta of 1.59. The firm’s 50-day simple moving average is $39.77 and its 200 day simple moving average is $56.76. Moderna, Inc. has a fifty-two week low of $30.70 and a fifty-two week high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05.
Moderna Company Profile
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
See Also
- Five stocks we like better than Moderna
- 3 Small Caps With Big Return Potential
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- How to Find Undervalued Stocks
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.